China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering RNA (siRNA) candidate, 2MW7141. The initiative follows an exclusive ...

Joe Jimenez, best known in biopharma as the ex-CEO of Novartis, has spent the last year-plus starting up something entirely different: a biotech investment firm focused on drug candidates that have ...

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 ...

(MENAFN- PR Newswire) Vitalli Bio is the ninth company formed by Aditum Bio OAKLAND, Calif., April 27, 2023 /PRNewswire/ -- Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis ...

Joe Jimenez, a former Novartis CEO, and Mark Fishman, the former head of the Novartis Institutes for BioMedical Research, announced a new biotech startup on Monday: Tempero Bio. The two are backing ...

SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 /PRNewswire/ -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in ...

Joe Jimenez’s VC fund has ponied up $10 million to try to crack a nut that defeated a who’s who of top drug developers. The outlay gives the fund, Aditum Bio, near-global rights to a BTK inhibitor ...

OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for ...

NANJING, China, Nov. 7, 2024 /PRNewswire/ -- Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license ...